No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon {beta}1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)

Conclusions:
Our results suggest that the combination of atorvastatin and interferon β1b is not justified in early relapsing–remitting multiple sclerosis and adds to the body of evidence indicating an absence of significant radiological and clinical benefit of statins in relapsing–remitting multiple sclerosis.

Source: Multiple Sclerosis - July 25, 2016 Category: Neurology Authors: Lanzillo, R., Quarantelli, M., Pozzilli, C., Trojano, M., Amato, M. P., Marrosu, M. G., Francia, A., Florio, C., Orefice, G., Tedeschi, G., Bellantonio, P., Annunziata, P., Grimaldi, L. M., Comerci, M., Brunetti, A., Bonavita, V., Alfano, B., Marini, S., Tags: Original Research Papers Source Type: research